Synapse - Works

Results (13087)

Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma: Assessment of risk factors

Meeting Abstract

Jonsdottir, G.; Bjorkholm, M.; Turesson, I.; Hultcrantz, M.; Porwit, A.; Jethava, Y.; Landgren, O.; Kristinsson, S. Y.
Blood (2017)

Fulltext@MSK | Save

Early results from a biomarker-directed phase 2 trial of SY-1425 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) demonstrate DHRS3 induction and myeloid differentiation following Sy-1425 treatment

Meeting Abstract

Jurcic, J. G.; Raza, A.; Vlad, G.; Stein, E. M.; Roshal, M.; Bixby, D. L.; Boyer, D. F.; Vigil, C. E.; Syrbu, S.; Sekeres, M. A.; more...
Blood (2017)

Fulltext@MSK | Save

Genomic characteristics clinical phenotype and disease course of TP53 mutated diffuse large B cell lymphoma at diagnosis and relapse

Meeting Abstract

Joffe, E.; Batlevi, C. L.; Intlekofer, A. M.; Zelenetz, A. D.; Moskowitz, C. H.; Palomba, M. L.; Noy, A.; Straus, D. J.; Portlock, C. S.; Gerecitano, J.; more...
Blood (2017)

Fulltext@MSK | Save

Single-cell methylome and transcriptome high-resolution maps define the effects of epigenetic modifiers on the landscape of hematopoietic differentiation

Meeting Abstract

Izzo, F.; Poran, A.; Lee, S. C. W.; Chaligne, R.; Gaiti, F.; Kothen-Hill, S.; Schulman, R.; Ki, M.; Ephraim, K.; Abdel-Wahab, O.; more...
Blood (2017)

Fulltext@MSK | Save

Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study

Meeting Abstract

Hofmeister, C. C.; Chari, A.; Cohen, Y.; Spencer, A.; Voorhees, P. M.; Estell, J.; Venner, C. P.; Sandhu, I.; Jenner, M. W.; Williams, C.; more...
Blood (2017)

Fulltext@MSK | Save

Interim results from a phase 1 study of ADCT-301 (camidanlumab tesirine) show promising activity of a novel pyrrolobenzodiazepine-based antibody drug conjugate in relapsed/refractory Hodgkin/non-Hodgkin lymphoma

Meeting Abstract

Horwitz, S. M.; Hamadani, M.; Fanale, M. A.; Feingold, J.; Spira, A. I.; Fields, P. A.; Menne, T.; Karnad, A.; Moskowitz, A. J.; Hildyard, C.; more...
Blood (2017)

Fulltext@MSK | Save

Prognostic utility of serum TARC, MDC, IL10, and soluble CD163 levels with positron emission tomography (PET) response-adapted therapy for advanced-stage Hodgkin lymphoma (HL): A SWOG S0816 US Intergroup correlative study

Meeting Abstract

Hsi, E. D.; Li, H.; Nixon, A. B.; Evens, A. M.; Schoder, H.; Straus, D. J.; Bartlett, N. L.; Sweetenham, J. W.; Barr, P. M.; Fanale, M. A.; more...
Blood (2017)

Fulltext@MSK | Save

Updated analyses of the international, open-label, randomized, phase 3 alcanza study: Longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T-cell lymphoma (CTCL)

Meeting Abstract

Horwitz, S. M.; Scarisbrick, J. J.; Dummer, R.; Duvic, M.; Kim, Y. H.; Walewski, J.; Whittaker, S.; Quaglino, P.; Zinzani, P. L.; Wolter, P.; more...
Blood (2017)

Fulltext@MSK | Save

RUNX1 deficiency and SRSF2 mutation cooperate to promote myelodysplastic syndrome development

Meeting Abstract

Huang, Y. J.; Yan, M.; Kim, E.; Davis, A. G.; Shima, T.; Miyauchi, S.; Fu, X. D.; Abdel-Wahab, O.; Zhang, D. E.
Blood (2017)

Fulltext@MSK | Save

Tumor-intrinsic RIG-I signaling promotes anti-CTLA-4 checkpoint inhibitor-mediated anticancer immunity

Meeting Abstract

Heidegger, S.; Wintges, A.; Bek, S.; Schmickl, M.; Ruland, J.; van den Brink, M. R. M.; Peschel, C.; Haas, T.; Poeck, H.
Blood (2017)

Fulltext@MSK | Save